Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | DRD4 | P21917 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.61 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.61 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.61 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11515734 | 0.98 | SLC2A1 (0.72) | SLC2A1SIGMAR1ADRB2DRD2DRD1 | |
| SCHEMBL27849455 | 0.94 | SLC2A1 (0.85) | SLC2A1SIGMAR1ADRB2DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL10452455 | 0.93 | SLC2A1 (0.87) | SLC2A1SIGMAR1ADRB2DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL7272231 | 0.93 | SLC2A1 (0.87) | SLC2A1SIGMAR1ADRB2DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL7282863 | 0.93 | SLC2A1 (0.70) | SLC2A1SIGMAR1ADRB2DRD2DRD1 | |
| SCHEMBL7279400 | 0.92 | ALDH1A1 (0.72) | SLC2A1SIGMAR1ADRB2SMN1; SMN2ALDH1A1 | |
| SCHEMBL13344551 | 0.92 | SLC2A1 (0.87) | SLC2A1SIGMAR1ADRB2DRD2DRD1 | |
| SCHEMBL7271665 | 0.91 | SLC2A1 (0.64) | SLC2A1SIGMAR1ADRB2DRD2DRD1 | |
| SCHEMBL7271671 | 0.91 | SLC2A1 (0.64) | SLC2A1SIGMAR1ADRB2DRD2DRD1 | |
| SCHEMBL7435099 | 0.91 | ATM (0.76) | SLC2A1SIGMAR1ADRB2POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
| EP-2598110-B1 | SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES | UNILEVER PLC (GB) | 2015-09-02 | — | — | EP | disclosed |
| EP-2598110-A2 | SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES | Unilever PLC (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-8293218-B2 | Skin care compositions comprising substituted monoamines | CONOPCO, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293218-B2 | Skin care compositions comprising substituted monoamines | CONOPCO, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293218-B2 | Skin care compositions comprising substituted monoamines | CONOPCO, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120027699-A1 | SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES | CONOPCO, INC., D/B/A UNILEVER (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027699-A1 | SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES | CONOPCO, INC., D/B/A UNILEVER (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027699-A1 | SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES | CONOPCO, INC., D/B/A UNILEVER (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012013418-A2 | SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES | UNILEVER PLC (GB) | 2012-02-02 | — | — | WO | disclosed |
| US-4187314-A | DOPAMINERGIC ACTIVITY | SMITHKLINE CORPORATION (US) | 1980-02-05 | — | — | US | disclosed |
| US-4175136-A | N-Phenethyl-N-propyl-3,4-dihydroxyphenethylamines and salts thereof | ROUSSEL UCLAF (FR) | 1979-11-20 | — | — | US | disclosed |
| US-4111957-A | DOPAMINERGIC | SMITHKLINE CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | SLC2A1 3939/4885SIGMAR1 3566/4885ADRB2 888/4885 |
| US-20120027699-A1 | SKIN CARE COMPOSITIONS COMPRISING SUBSTITUTED MONOAMINES | TYR, CUTA, MAOA | SLC2A1 1813/4885SIGMAR1 1071/4885ADRB2 49/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | SLC2A1 4086/4885SIGMAR1 4340/4885ADRB2 650/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | SLC2A1 3939/4885SIGMAR1 3566/4885ADRB2 888/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | SLC2A1 4202/4885SIGMAR1 3016/4885ADRB2 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.